Rearrangements of the MLL Gene Are Influenced by DNA Secondary Structure, Potentially Mediated by Topoisomerase II Binding

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3105-3105
Author(s):  
Hongan Le ◽  
Sabine Schnyder ◽  
Nga Du ◽  
Grace Loredo ◽  
Sheetal Singh ◽  
...  

Abstract Rearrangements of the MLL gene are found in approximately 75–80% of both infant acute leukemia (IAL) and therapy related myeloid leukemia (tAML), the latter linked to prior exposure to Topoisomerase II inhibitors. In order to study the mechanism whereby such rearrangements are induced, a fine mapping screen was performed using Inverse PCR to analyze a MLL location at the intron 11/exon 12 border that is known to be a hot spot for the induction of DNA breaks and rearrangements. Human lymphoblastoid TK6 cells were exposed to the pro-apoptotic agent anti-CD95 and estrogen as both the apoptotic process and birth control formulations have been associated with the development of MLL-linked leukemia. The latter association was determined as part of an epidemiological analysis of IAL. In addition, blood samples from patients receiving Topoisomerase II inhibitor therapy, subsequent to a diagnosis of breast cancer or lymphoma, were examined in the same manner as such drugs are strongly associated with the etiology of tAML. From an initial screen of cells treated in-vitro, 13/27 of all rearrangement break points (translocations/insertions) were located within a 3 bp tract at the 5′ edge of a 10 bp palindrome that defined a potential 101 bp stem-loop with its 3′ palindrome partner. Analysis of blood samples taken up to a year after treatment initiation from lymphoma and breast cancer patients, showed a similar distribution of translocations with 10/20 events restricted to the same location on the 5′ of the palindrome. Further examination of the putative stem-loop structure showed a high stringency Topoisomerase II consensus sequence binding site at the geometric midpoint of the proposed stem-loop. In order to link the rearrangements observed with DNA cleavage events, TK6 cells exposed to anti-CD95 antibody were also screened for DNA breaks within the same region of MLL. Here, LM-PCR products spanning the region of interest were extracted from DNA gels and the location of cleavage determined by cloning and sequencing. From four to twenty four hours after anti-CD95 exposure, analysis of the breaks induced showed 24/37 (65%) were located at the base of the proposed stem loop associated with the DNA palindrome. 14/37 (38%) of breaks were found within a 40 bp tract at the 5′ side and 10/37 (27%) within a 20 bp tract at the 3′ side of the palindrome base. In each case, the hot spots for cleavage identified by LM-PCR included the palindromic sequences. Thus, unlike the 5′ restriction of MLL rearrangements, DNA fragmentation occurred at both sides of the proposed stem loop base, indirectly supporting the creation of such a structure in-vivo that is subject to local attack at the stem base. Palindrome association may be driven by the bending Topoisomerase II exerts when bound at the midpoint between each palindrome, such that each half of the proposed palindrome is brought into physical contact. This effect would be accentuated by poisoning of Topoisomerase II, subsequent to binding of drugs such as etoposide that stabilize the cleavable complex. We propose a model for a sub-group of MLL rearrangements that utilize Topoisomerase II mediated stabilization, either natively or subsequent to chemical poisoning, to assist in the creation of stable DNA structures that are permissive for DNA fragmentation. Further, the conversion of DNA double strand breaks at these sites to detectable rearrangements may be influenced by 5′ to 3′ DNA processing functions, such as transcription or replication.

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A168-A168
Author(s):  
Eric Lutz ◽  
Lakshmi Rudraraju ◽  
Elizabeth DeOliveira ◽  
Amanda Seiz ◽  
Monil Shah ◽  
...  

BackgroundMarrow infiltrating lymphocytes (MILsTM) are the product of activating and expanding bone marrow T cells.1 The bone marrow is a specialized niche in the immune system enriched for antigen-experienced, memory T cells. In patients with multiple myeloma and other hematological malignancies that relapse post-transplant, MILs have been shown to contain tumor antigen-specific T cells and adoptive cell therapy (ACT) using MILs has demonstrated antitumor activity.2 3 The bone marrow has been shown to harbor tumor-antigen specific T cells in patients with melanoma,4 5 glioblastoma,6 breast,7 non-small-cell lung8 and pancreatic cancers.9 Here, we sought to determine if tumor-specific MILs could be expanded from the bone marrow of patients with a range of different solid tumors.MethodsBone marrow and blood samples were collected from patients with advanced and metastatic cancers. To date, samples have been collected from a minimum of four patients with non-small cell lung cancer (NSCLC), prostate cancer, head and neck cancer, glioblastoma, and breast cancer. Samples from patients with multiple myeloma were used as a reference control. Utilizing a 10-day proprietary process, MILs and peripheral blood lymphocytes (PBLs) were activated and expanded from patient bone marrow and blood samples, respectively. T cell lineage-specific markers (CD3, CD4 and CD8) were characterized by flow cytometry pre- and post-expansion.Tumor-specific T cells were quantitated in expanded MILs and PBLs using a previously described cytokine-secretion assay [2]. Briefly, autologous antigen-presenting cells (APCs) were pulsed with lysates from allogeneic cancer cell lines and co-cultured with activated MILs or PBLs. APCs pulsed with irrelevant mis-matched cancer cell line lysates or media alone were used as negative controls. Tumor-specific T cells were defined as the IFNgamma-producing population by flow cytometry.ResultsMILs were successfully expanded from all patient bone marrow samples tested, regardless of tumor type. Cytokine-producing tumor-specific CD4+ and CD8+ T cells were detected in each of the expanded MILs. In contrast, tumor-specific T cells were not detected in any of the matched activated and expanded PBLs.ConclusionsMILs have been successfully grown for all solid tumor types evaluated, including NSCLC, prostate, head and neck, glioblastoma and breast cancer. Clinical studies have been completed in patients with multiple myeloma and other hematological cancers. 2 3 A phase IIa trial to evaluate MILs in combination with a checkpoint inhibitor is underway in patients with anti-PD1/PDL1-refractory NSCLC (ClinicalTrials.gov Identifier: NCT04069936). The preclinical data presented herein demonstrate that expanding MILs is feasible. MILs-based therapies hold therapeutic promise across a wide range of tumor indications.Ethics ApprovalThis study was approved by each participating instituion’s IRB.ReferencesBorrello I and Noonan KA. Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy. Front Immunol 2016 March 30; 7(112)Noonan KA, Huff CA, Davis J, et al. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci. Transl. Med 2015;7:288ra78.Biavati L, Noonan K, Luznik L, Borrello I. Activated allogeneic donor-derived marrow-infiltrating lymphocytes display measurable in vitro antitumor activity. J Immunother 2019 Apr;42(3):73–80.Müller-Berghaus J, Ehlert K, Ugurel S, et al. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res 2006;66(12):5997–6001.Letsch A, Keilholz U, Assfalg G, et al., Bone marrow contains melanoma-reactive CD8+ effector T Cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. Cancer Res 2003 Sep 1;63(17):5582–5586.Chongsathidkiet P, Jackson C, Koyama S, et al., Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine 2018 Aug 13; 24:1459–1468.Feuerer M, Rocha M, Bai L, et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001; 92(1):96–105.Safi S, Yamauchi Y, Stamova S, et al. Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer. Oncoimmunology 2019;8(12):e1671762.Schmitz-Winnenthal FH, Volk C, Z’Graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65(21):10079–87.


2019 ◽  
Vol 32 (2) ◽  
pp. 408-414
Author(s):  
Revathy Selvaraj ◽  
J. Suresh ◽  
A. Arun

In this work, we have synthesized efficient antibacterial compounds with anticancer novel molecules based on cyanuric chloride containing chalcone moiety. For this, novel triazine-based organic molecules were synthesized by using cyanuric chloride and 2,4-dichloro-1-ene(4-hydroxyphenyl)phenone and characterized by elemental analysis, FT-IR, NMR and UV-visible spectrometry techniques. Melting point of the molecules were increased with an increase in substitution on cyanuric chloride. The minimum inhibitory concentration (MIC) value of the synthesized compounds showed an excellent result on Gram-negative bacteria with low MIC value of 1.95 μg/mL. Gram-positive bacteria showed little resistance to the synthesized drug. The synthesized compounds were tested for their use as an anticancer drug using in silico screening method. The synthesized compounds in silico molecular docking method using breast cancer protein (BRCA2) confirms that triazine derivative with all three chlorine molecules replaced by 2,4-dichloro-1-ene(4-hydroxyphenyl)phenone showed highest binding energy with the value of -9.1900 Kcal/mol which is in agreement with the observed high MIC value obtained for Gram-negative bacteria. The synthesized molecules preferentially targeted the topoisomerase II of the bacteria. Overall, an efficient antimicrobial drug is synthesized using a simple preparation method.


Nanoscale ◽  
2018 ◽  
Vol 10 (34) ◽  
pp. 16307-16313 ◽  
Author(s):  
Richard D. Lin ◽  
Nicole F. Steinmetz

Tobacco mosaic virus-nanoparticle encapsulation of the topoisomerase II inhibitor mitoxantrone enables therapy in a mouse model of triple negative breast cancer.


Breast Cancer ◽  
1998 ◽  
Vol 5 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Shunzo Kobayashi ◽  
Hirotaka Iwase ◽  
Yoshihiko Kawarada ◽  
Naoyuki Miura ◽  
Toshihiro Sugiyama ◽  
...  

2013 ◽  
Vol 9 (5) ◽  
pp. 747-752 ◽  
Author(s):  
Ulrich Andergassen ◽  
Michael Zebisch ◽  
Alexandra C Kölbl ◽  
Christian Schindlbeck ◽  
Matthias Ilmer ◽  
...  

2015 ◽  
Vol 31 (8) ◽  
pp. 815-822 ◽  
Author(s):  
Fei GAO ◽  
Feng LIU ◽  
Jing ZHENG ◽  
MeiYun ZENG ◽  
Yuyang JIANG

Author(s):  
Stamatios Karavolos

AbstractSperm DNA fragmentation refers to the accumulation of adducts as well as single- or double-strand DNA breaks and reflects the sperm DNA quality. Current data suggest that there are differences in sperm DNA quality among individuals with high or low fertility, and this observation has led to the idea that testing sperm DNA fragmentation could be a useful test of male fertility. However, sperm DNA fragmentation has become one of the most frequently debated topics in reproductive medicine, as there is no agreement about the optimal way to test for DNA fragmentation, the clinically significant level of sperm DNA fragmentation, as well as the best therapeutic options for infertile men. This article presents current evidence related to sperm DNA fragmentation and its role in managing male infertility.


Pathobiology ◽  
2000 ◽  
Vol 68 (3) ◽  
pp. 137-143 ◽  
Author(s):  
Lydia Nakopoulou ◽  
Andreas C. Lazaris ◽  
Nikolaos Kavantzas ◽  
Paraskevi Alexandrou ◽  
Pauline Athanassiadou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document